West Pharma (WST) Tops Q4 EPS by 20c, provides guidance
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $346.23 +0.58%
Revenue Growth %: +2.5%
Financial Fact:
Equity in net income of affiliated companies: 2.7M
Today's EPS Names:
ANAB, ANIX, MNY, More
Revenue Growth %: +2.5%
Financial Fact:
Equity in net income of affiliated companies: 2.7M
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
West Pharma (NYSE: WST) reported Q4 EPS of $2.04, $0.20 better than the analyst estimate of $1.84. Revenue for the quarter came in at $805 million versus the consensus estimate of $796.25 million.
GUIDANCE:
West Pharma sees FY2026 EPS of $7.85-$8.20, versus the consensus of $7.76.
For earnings history and earnings-related data on West Pharma (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Corning (GLW) files for up to $2B offering of common shares
- GMR Solutions to reprice $2.9B term loan, pay down $200M in debt
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
